Skip to main content

Table 3 Median results for single-agent cytotoxics tested compared with results when tested in combination with gefitinib.

From: The in vitroeffect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

Drug/Combination

N

AUC

IC90

IC50

IndexSUM

% showing decrease in IndexSUM when in combination with gefitinib

Gefitinib

86

3943 (40–13212)

646 (243–12614)

399 (4–7008)

570 (187–818)

-

Cisplatin

6

7937 (4244–9804)

294 (208–557)

132 (84–309)

434 (382–497)

-

Cisplatin + gefitinib

6

9006 (1731–12057)

225 (159–585)

107 (58–325)

486 (351–588)

33% (2/6)

Gemcitabine

2

7127 (498–13756)

764 (206–1321)

382 (30–734)

452 (288–616)

-

Gemcitabine + gefitinib

2

12605 (9835–15374)

211 (201–220)

52 (17–86)

315 (207–422)

100% (2/2)

Oxaliplatin

10

3488 (874–8884)

833 (317–2267)

463 (129–1259)

559 (379–681)

-

Oxaliplatin + gefitinib

10

5602 (547–12140)

390 (194–775)

217 (60–431)

447 (310–605)

90% (9/10)

Treosulfan

34

13764 (4351–18390)

146 (35–616)

53 (4–342)

353 (65–726)

-

Treosulfan + gefitinib

34

13656 (4251–18658)

153 (31–19892)

60 (4–11051)

338 (58–897)

56% (19/34)

Treosulfan + gemcitabine

24

17576 (8107–19164)

57 (6–200)

13 (3–110)

155 (21–456)

-

Treosulfan + gemcitabine+ gefitinib

24

17281 (11402–19119)

48 (9–206)

9 (4–70)

146 (25–572)

54% (13/24)